ReviewItalian journal of pediatrics2025
Eosinophilic gastroduodenitis: a pediatric perspective.
Review in Italian journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Eosinophilic gastroduodenitis (EoGD) is a group of chronic inflammatory disorders characterized by an increased presence of eosinophils in the stomach and duodenum. Although relatively rare, it is an increasingly recognized form of eosinophilic gastrointestinal diseases (EGIDs) with significant clinical implications, particularly in pediatric patients. Despite advancements in diagnostic tools, considerable delays in diagnosis persist due to the nonspecific nature of clinical manifestations, which often resemble more common gastrointestinal disorders. Early referral to a gastroenterologist is critical, especially when patients present with persistent gastrointestinal signs and symptoms that do not improve with treatment for common conditions like irritable bowel syndrome. Food allergens and microbiota may play a role in the pathogenesis of this disease. Management typically involves a combination of dietary modifications, pharmacological treatments such as corticosteroids, and, in some cases, biologic agents targeting eosinophilic inflammation. However, long-term outcomes remain variable, and data on prognosis are still limited, underscoring the need for further research. Future studies should focus on validating new diagnostic markers and therapeutic strategies, better understanding long-term outcomes, and developing personalized treatment plans. A multidisciplinary approach, incorporating the expertise of gastroenterologists, allergists, dietitians, and surgeons, is crucial to ensure optimal patient care and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.